Cyclerion Therapeutics Statistics
Total Valuation
CYCN has a market cap or net worth of $6.39 million. The enterprise value is $1.83 million.
Important Dates
The last earnings date was Wednesday, November 12, 2025, after market close.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CYCN has 3.81 million shares outstanding. The number of shares has increased by 14.72% in one year.
| Current Share Class | 3.81M |
| Shares Outstanding | 3.81M |
| Shares Change (YoY) | +14.72% |
| Shares Change (QoQ) | +5.01% |
| Owned by Insiders (%) | 19.33% |
| Owned by Institutions (%) | 19.63% |
| Float | 3.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.69 |
| Forward PS | n/a |
| PB Ratio | 0.65 |
| P/TBV Ratio | 0.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.78
| Current Ratio | 5.78 |
| Quick Ratio | 5.32 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -24.80% and return on invested capital (ROIC) is -25.60%.
| Return on Equity (ROE) | -24.80% |
| Return on Assets (ROA) | -23.51% |
| Return on Invested Capital (ROIC) | -25.60% |
| Return on Capital Employed (ROCE) | -38.09% |
| Revenue Per Employee | $2.86M |
| Profits Per Employee | -$2.20M |
| Employee Count | 1 |
| Asset Turnover | 0.30 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.54% in the last 52 weeks. The beta is 0.94, so CYCN's price volatility has been similar to the market average.
| Beta (5Y) | 0.94 |
| 52-Week Price Change | -73.54% |
| 50-Day Moving Average | 1.92 |
| 200-Day Moving Average | 2.60 |
| Relative Strength Index (RSI) | 50.95 |
| Average Volume (20 Days) | 1,065,392 |
Short Selling Information
The latest short interest is 335,301, so 8.81% of the outstanding shares have been sold short.
| Short Interest | 335,301 |
| Short Previous Month | 102,981 |
| Short % of Shares Out | 8.81% |
| Short % of Float | 10.92% |
| Short Ratio (days to cover) | 0.38 |
Income Statement
In the last 12 months, CYCN had revenue of $2.86 million and -$2.20 million in losses. Loss per share was -$0.77.
| Revenue | 2.86M |
| Gross Profit | 2.65M |
| Operating Income | -3.63M |
| Pretax Income | -2.20M |
| Net Income | -2.20M |
| EBITDA | n/a |
| EBIT | -3.63M |
| Loss Per Share | -$0.77 |
Full Income StatementBalance Sheet
The company has $4.57 million in cash and n/a in debt, giving a net cash position of $4.57 million or $1.20 per share.
| Cash & Cash Equivalents | 4.57M |
| Total Debt | n/a |
| Net Cash | 4.57M |
| Net Cash Per Share | $1.20 |
| Equity (Book Value) | 9.54M |
| Book Value Per Share | 2.58 |
| Working Capital | 4.19M |
Full Balance SheetCash Flow
| Operating Cash Flow | -1.38M |
| Capital Expenditures | n/a |
| Free Cash Flow | -1.38M |
| FCF Per Share | -$0.36 |
Full Cash Flow StatementMargins
Gross margin is 92.64%, with operating and profit margins of -127.25% and -77.02%.
| Gross Margin | 92.64% |
| Operating Margin | -127.25% |
| Pretax Margin | -77.02% |
| Profit Margin | -77.02% |
| EBITDA Margin | n/a |
| EBIT Margin | -127.25% |
| FCF Margin | n/a |